GALT — Galectin Therapeutics Share News
0.000.00%
Last trade - 00:00- $340.87m
- $465.30m
Galectin Therapeutics slumps after liver disease drug fails in study
U.S. STOCKS ON THE MOVE-Mission Produce, Sirius XM, Carnival Corp
Brief: Galectin Therapeutics Inc - Belapectin Well Tolerated With No Safety Signals
U.S. STOCKS ON THE MOVE-Humacyte, Ionis Pharmaceuticals, Emeren Group
Galectin Therapeutics falls after liver disease drug fails to meet main goal in study
Galectin Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Galectin Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Galectin Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Galectin Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Galectin Therapeutics Inc reports results for the quarter ended in January - Earnings Summary
Galectin Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Galectin Reports Outcome Of Fifth DSMB Meeting For Phase 2B/3 Study Of Belapectin In Patients With Cirrhotic Portal Hypertension
Galectin Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Galectin Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Galectin Therapeutics Reports The Positive Outcome Of The Fourth Data And Safety Monitoring Board Meeting For Navigate
Galectin Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Galectin Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview
Galectin Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Galectin Therapeutics Inc Reports Quarterly Loss Per Share $0.19